Literature DB >> 20484105

Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis.

An Hendrix1, Dawn Maynard, Patrick Pauwels, Geert Braems, Hannelore Denys, Rudy Van den Broecke, Jo Lambert, Simon Van Belle, Veronique Cocquyt, Christian Gespach, Marc Bracke, Miguel C Seabra, William A Gahl, Olivier De Wever, Wendy Westbroek.   

Abstract

BACKGROUND Secretory GTPases like Rab27B control vesicle exocytosis and deliver critical proinvasive growth regulators into the tumor microenvironment. The expression and role of Rab27B in breast cancer were unknown. METHODS Expression of green fluorescent protein (GFP) fused with wild-type Rab3D, Rab27A, or Rab27B, or Rab27B point mutants defective in GTP/GDP binding or geranylgeranylation, or transient silencing RNA to the same proteins was used to study Rab27B in estrogen receptor (ER)-positive human breast cancer cell lines (MCF-7, T47D, and ZR75.1). Cell cycle progression was evaluated by flow cytometry, western blotting, and measurement of cell proliferation rates, and invasion was assessed using Matrigel and native type I collagen substrates. Orthotopic tumor growth, local invasion, and metastasis were analyzed in mouse xenograft models. Mass spectrometry identified proinvasive growth regulators that were secreted in the presence of Rab27B. Rab27B protein levels were evaluated by immunohistochemistry in 59 clinical breast cancer specimens, and Rab3D, Rab27A, and Rab27B mRNA levels were analyzed by quantitative real-time polymerase chain reaction in 20 specimens. Statistical tests were two-sided. RESULTS Increased expression of Rab27B promoted G(1) to S phase cell cycle transition, proliferation and invasiveness of cells in culture, and invasive tumor growth and hemorrhagic ascites production in a xenograft mouse model (n = 10; at 10 weeks, survival of MCF-7 GFP- vs GFP-Rab27B-injected mice was 100% vs 62.5%, hazard ratio = 0.26, 95% confidence interval = 0.08 to 0.88, P = .03). Mass spectrometric analysis of purified Rab27B-secretory vesicles identified heat-shock protein 90alpha as key proinvasive growth regulator. Heat-shock protein 90alpha secretion was Rab27B-dependent and was required for matrix metalloproteinase-2 activation. All Rab27B-mediated functional responses were GTP- and geranylgeranyl-dependent. Presence of endogenous Rab27B mRNA and protein, but not of Rab3D or Rab27A mRNA, was associated with lymph node metastasis (P < .001) and differentiation grade (P = .001) in ER-positive human breast tumors. CONCLUSIONS Rab27B regulates invasive growth and metastasis in ER-positive breast cancer cell lines, and increased expression is associated with poor prognosis in humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484105      PMCID: PMC2886092          DOI: 10.1093/jnci/djq153

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  56 in total

Review 1.  Rab proteins as membrane organizers.

Authors:  M Zerial; H McBride
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

Review 2.  Constitutive and regulated secretion of proteins.

Authors:  T L Burgess; R B Kelly
Journal:  Annu Rev Cell Biol       Date:  1987

3.  Rab23 is a potential biological target for treating hepatocellular carcinoma.

Authors:  Yun-Jian Liu; Qian Wang; Wen Li; Xiao-Hui Huang; Mao-Chuan Zhen; Shu-Hong Huang; Lian-Zhou Chen; Ling Xue; Hong-Wei Zhang
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

4.  High HSP90 expression is associated with decreased survival in breast cancer.

Authors:  Elah Pick; Yuval Kluger; Jennifer M Giltnane; Christopher Moeder; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

5.  Molecular cloning and characterization of rab27a and rab27b, novel human rab proteins shared by melanocytes and platelets.

Authors:  D Chen; J Guo; T Miki; M Tachibana; W A Gahl
Journal:  Biochem Mol Med       Date:  1997-02

6.  The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.

Authors:  Kwai Wa Cheng; John P Lahad; Wen-Lin Kuo; Anna Lapuk; Kyosuke Yamada; Nelly Auersperg; Jinsong Liu; Karen Smith-McCune; Karen H Lu; David Fishman; Joe W Gray; Gordon B Mills
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

7.  MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway.

Authors:  Jose J Bravo-Cordero; Raquel Marrero-Diaz; Diego Megías; Laura Genís; Aranzazu García-Grande; Maria A García; Alicia G Arroyo; María C Montoya
Journal:  EMBO J       Date:  2007-03-01       Impact factor: 11.598

8.  Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II.

Authors:  Jin-Song Wang; Fu-Bin Wang; Qiang-Ge Zhang; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

9.  A novel missense mutation (G43S) in the switch I region of Rab27A causing Griscelli syndrome.

Authors:  Wendy Westbroek; Maya Tuchman; Bradford Tinloy; Olivier De Wever; Thierry Vilboux; Jens M Hertz; Henrik Hasle; Carsten Heilmann; Amanda Helip-Wooley; Robert Kleta; William A Gahl
Journal:  Mol Genet Metab       Date:  2008-04-07       Impact factor: 4.797

10.  A biosynthetic regulated secretory pathway in constitutive secretory cells.

Authors:  R A Chavez; S G Miller; H P Moore
Journal:  J Cell Biol       Date:  1996-06       Impact factor: 10.539

View more
  102 in total

Review 1.  The role of endocytic Rab GTPases in regulation of growth factor signaling and the migration and invasion of tumor cells.

Authors:  N Porther; M A Barbieri
Journal:  Small GTPases       Date:  2015-08-20

2.  Identification of metastasis-associated genes in colorectal cancer through an integrated genomic and transcriptomic analysis.

Authors:  Xiaobo Li; Sihua Peng
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

Review 3.  Rho-kinase: regulation, (dys)function, and inhibition.

Authors:  Ehsan Amin; Badri Nath Dubey; Si-Cai Zhang; Lothar Gremer; Radovan Dvorsky; Jens M Moll; Mohamed S Taha; Luitgard Nagel-Steger; Roland P Piekorz; Avril V Somlyo; Mohammad R Ahmadian
Journal:  Biol Chem       Date:  2013-11       Impact factor: 3.915

4.  Cellular and clinical report of new Griscelli syndrome type III cases.

Authors:  Wendy Westbroek; Aharon Klar; Andrew R Cullinane; Shira G Ziegler; Haggit Hurvitz; Ashraf Ganem; Kirkland Wilson; Heidi Dorward; Marjan Huizing; Haled Tamimi; Igor Vainshtein; Yackov Berkun; Moran Lavie; William A Gahl; Yair Anikster
Journal:  Pigment Cell Melanoma Res       Date:  2011-10-03       Impact factor: 4.693

Review 5.  Going live with tumor exosomes and microvesicles.

Authors:  Vincent Hyenne; Olivier Lefebvre; Jacky G Goetz
Journal:  Cell Adh Migr       Date:  2017-01-31       Impact factor: 3.405

6.  Roles of Small GTPases in Acquired Tamoxifen Resistance in MCF-7 Cells Revealed by Targeted, Quantitative Proteomic Analysis.

Authors:  Ming Huang; Yinsheng Wang
Journal:  Anal Chem       Date:  2018-11-30       Impact factor: 6.986

Review 7.  Consequences of Rab GTPase dysfunction in genetic or acquired human diseases.

Authors:  Marcellus J Banworth; Guangpu Li
Journal:  Small GTPases       Date:  2017-12-28

Review 8.  Exosomes as agents of change in the cardiovascular system.

Authors:  A J Poe; A A Knowlton
Journal:  J Mol Cell Cardiol       Date:  2017-08-03       Impact factor: 5.000

9.  A Targeted Quantitative Proteomic Approach Assesses the Reprogramming of Small GTPases during Melanoma Metastasis.

Authors:  Ming Huang; Tianyu F Qi; Lin Li; Gao Zhang; Yinsheng Wang
Journal:  Cancer Res       Date:  2018-08-02       Impact factor: 12.701

10.  RNA sequencing of MCF-7 breast cancer cells identifies novel estrogen-responsive genes with functional estrogen receptor-binding sites in the vicinity of their transcription start sites.

Authors:  Ryonosuke Yamaga; Kazuhiro Ikeda; Kuniko Horie-Inoue; Yasuyoshi Ouchi; Yutaka Suzuki; Satoshi Inoue
Journal:  Horm Cancer       Date:  2013-03-23       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.